Treatment for HCV Slows Progression of CKD

Restricted access

Direct-acting antiviral therapy for hepatitis C virus (HCV) slows the decline in kidney function for patients with comorbid chronic kidney disease (CKD), reports a study in Kidney International.

The retrospective study included 1178 HCV-infected patients who started DAA therapy between 2013 and 2017. All included patients were compliant with DAA treatment, had not undergone organ transplantation or started dialysis, and had available data on baseline creatinine. The patients’ mean age was 46 years; 64% were male and 71% were white, 42% had cirrhosis, and 21% had diabetes. The slope of decline in estimated glomerular filtration rate (eGFR) was